Different clinical effects upon separate inhibition of coexisting EGFR and PI3KCA mutations in a lung adenocarcinoma patient. Issue 2 (February 2015)

• Record Type: Journal Article
• Authors: Tiseo, Marcello; Bersanelli, Melissa; Perrone, Federica; Tamborini, Elena; Settanni, Giulio; Busico, Adele; Rossi, Giulio; Ardizzoni, Andrea; Pelosi, Giuseppe
• Is Part Of: Lung cancer. Volume 87:Issue 2(2015:Feb.)
• Page Start: 204
• Page End: 206
• Publication Date: 2015-02
• Subjects: Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2014.12.008
• Languages: English
• ISSNs: 0169-5002

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">Mutations of <italic>PIK3CA</italic> characterize 2–4% of NSCLC.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010"> <italic>PIK3CA</italic> mutations are not-mutually-exclusive with other mutations.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">Shorter median survival was reported if concomitant <italic>PIK3CA</italic> and <italic>EGFR</italic> mutations.</p> </list-item> <list-item id="lsti0020"> <label></label> <p id="par0020">In this case, progression disease was reported with PI3K inhibitor.</p> </list-item> <list-item id="lsti0025"> <label></label> <p id="par0025">Benefit with EGFR-TKI is possible also with concomitant <italic>PIK3CA</italic> and <italic>EGFR</italic> mutations.</p> </list-item> </list> </p> </sec> </abstract>